Skip to Main Content Skip to Site Map Skip to Accessibility Statement
Home Formulary 2.0 Cardiovascular System 2.8 Anticoagulants and protamine 2.8.2 Oral anticoagulants 2.8.2.4 Acute coronary syndrome

2.8.2.4 Acute coronary syndrome

Rivaroxaban in Acute Coronary Syndrome

  • Refer to NICE TA335 – Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome.
  • In patients after acute coronary syndrome with elevated cardiac biomarkers, low dose rivaroxaban 2.5mg twice daily may be considered as an option, co administered with aspirin 75mg once daily, or with aspirin 75mg once daily plus clopidogrel 75mg once daily.
  • This should only be undertaken under specialist guidance.
  • Co-administration as per NICE TA335 may significantly increase bleeding risk and clinicians should carefully assess if bleeding risk outweighs potential benefit in individual patients.
  • Co-administration of rivaroxaban with newer P2Y12 drugs (prasugrel or ticagrelor) is not currently recommended.
  • Treatment discontinuation may be considered at 12 months because experience of treatment beyond this is limited.

Also in this Section